ArticleEuropean journal of case reports in internal medicine2025
Uncovering the Cause of Pneumonia: Reactivation of HHV-6B in an Immunocompromised Patient.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human herpesvirus 6 (HHV-6) is a ubiquitous virus that commonly infects the paediatric population and establishes latency in the host following primary infection. As in other herpesviruses, HHV-6 may reactivate when the immune system becomes severely compromised, such as after chemotherapy or haematopoietic cell transplantation. We report a case of an 83-year-old male, previously diagnosed with multiple myeloma and treated with lenalidomide plus bortezomib, who was admitted to the internal medicine department with bilateral pulmonary thromboembolism. During his stay, he developed severe respiratory dysfunction and fever. A diagnosis of nosocomial pneumonia was established based on imaging and blood tests. Despite broad-spectrum antibiotic therapy the patient remained febrile with worsening respiratory function and developed an erythematous rash on the face and trunk. The chest CT scan revealed scattered ground-glass opacities bilaterally. Investigations for opportunistic agents (serologies and DNA) were also performed, with positive IgM cytomegalovirus (CMV) antibodies, but negative CMV antigen and DNA quantification, while serum DNA was positive for HHV-6. Antibiotics were discontinued and bronchoalveolar lavage (BAL) was performed with HHV-6 polymerase chain reaction (PCR) testing positive, identifying HHV-6B. Treatment with intravenous ganciclovir led to the resolution of symptoms and hypoxaemia. The patient was discharged and completed 21 days of valganciclovir at home. After one year, the patient remains on chemotherapy without pulmonary sequelae or new HHV-6B reinfection. LEARNING POINTS: Human herpesvirus 6 (HHV-6) can reactivate in immunocompromised individuals and cause severe atypical pneumonia, so it is important to recognise this entity when a patient fails to improve their clinical outcome with conventional therapy.In patients diagnosed with pneumonitis, DNA PCR testing can detect HHV-6 from bronchoalveolar lavage fluid making this a powerful diagnostic tool.Treatment options for HHV-6 pneumonitis should be considered, such as combined ganciclovir and foscarnet or, as in our case, oral valganciclovir can be a good alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.